The incidence and mortality of colorectal cancer (CRC) have always been among the highest in the world, although the diagnosis and treatment are becoming more and more advanced. At present, the main reason is that patients have acquired drug resistance after long-term conventional drug treatment. An increasing number of evidences confirm the existence of cancer stem cells (CSCs), which are a group of special cells in cancer, only a small part of cancer cells. These special cell populations are not eliminated by chemotherapeutic drugs and result in tumor recurrence and metastasis after drug treatment. CSCs have the ability of self-renewal and multidirectional differentiation, which is associated with the occurrence and development of cancer. CSCs can be screened and identified by related surface markers. In this paper, the characteristic surface markers of CSCs in CRC and the related mechanism of drug resistance will be discussed in detail. A better understanding of the mechanism of CSCs resistance to chemotherapy may lead to better targeted therapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
All data and materials could be found in our published paper.
Siegel RL, et al. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
Siegel RL, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
Vodenkova S, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.
Andrei L, et al. Advanced technological tools to study multidrug resistance in cancer. Drug Resist Updat. 2020;48:100658.
Maugeri-Saccà M, et al. Cancer stem cells and chemosensitivity. Clin Cancer Res. 2011;17(15):4942–7.
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.
Ma L, et al. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells. Tumour Biol. 2016;37(9):12889–96.
Munro MJ, et al. Cancer stem cells in colorectal cancer: a review. J Clin Pathol. 2018;71(2):110–6.
Dontu G, et al. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004;15(5):193–7.
Collins AT, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51.
O’Brien CA, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.
Catalano V, et al. CD133 as a target for colon cancer. Expert Opin Ther Targets. 2012;16(3):259–67.
Fan CW, et al. Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies. Cell Death Dis. 2013;4(10):e828.
Yeung TM, et al. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A. 2010;107(8):3722–7.
Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50(6):285–98.
Najafi M, et al. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.
Morgan RG, et al. Targeting LGR5 in colorectal cancer: therapeutic gold or too plastic? Br J Cancer. 2018;118(11):1410–8.
McClanahan T, et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther. 2006;5(4):419–26.
Barker N, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457(7229):608–11.
Barker N, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 2010;6(1):25–36.
Baker AM, et al. Characterization of LGR5 stem cells in colorectal adenomas and carcinomas. Sci Rep. 2015;5:8654.
Liu YS, et al. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer. Biomed Pharmacother. 2013;67(8):791–9.
Wu W, et al. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer. Oncotarget. 2016;7(49):81144–55.
Kobayashi S, et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells. 2012;30(12):2631–44.
Al-Othman N, et al. Role of CD44 in breast cancer. Breast Dis. 2020;39(1):1–13.
Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J. 2015;36(3):273–9.
Wang L, et al. The role of CD44 and cancer stem cells. Methods Mol Biol. 2018;1692:31–42.
Morath I, et al. CD44: more than a mere stem cell marker. Int J Biochem Cell Biol. 2016;81(Pt A):166–73.
Toden S, et al. Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight. 2019; 4(6).
Todaro M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56.
Yoon C, et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20(15):3974–88.
Matzke-Ogi A, et al. Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling. Gastroenterology. 2016;150(2):513-25.e10.
Jang JW, et al. Potential mechanisms of CD133 in cancer stem cells. Life Sci. 2017;184:25–9.
Corbeil D, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000;275(8):5512–20.
Giebel B, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 2004;104(8):2332–8.
Akbari M, et al. CD133: An emerging prognostic factor and therapeutic target in colorectal cancer. Cell Biol Int. 2020;44(2):368–80.
Hatina J, et al. Ovarian cancer stem cell heterogeneity. Adv Exp Med Biol. 2019;1139:201–21.
Ricci-Vitiani L, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.
Aghajani M, et al. New emerging roles of CD133 in cancer stem cell: signaling pathway and miRNA regulation. J Cell Physiol. 2019;234(12):21642–61.
Soeda A, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009;28(45):3949–59.
Cai C, et al. Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2017;46(1):36–43.
Todaro M, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389–402.
Todaro M, et al. Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010;138(6):2151–62.
Galizia G, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 2012;147(1):18–24.
Toledo-Guzmán ME, et al. ALDH as a stem cell marker in solid tumors. Curr Stem Cell Res Ther. 2019;14(5):375–88.
Tomita H, et al. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10):11018–32.
Kashii-Magaribuchi K, et al. Induced expression of cancer stem cell markers ALDH1A3 and Sox-2 in hierarchical reconstitution of apoptosis-resistant human breast cancer cells. Acta Histochem Cytochem. 2016;49(5):149–58.
Feng H, et al. ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 status. Br J Cancer. 2018;118(2):224–32.
Flahaut M, et al. Aldehyde dehydrogenase activity plays a key role in the aggressive phenotype of neuroblastoma. BMC Cancer. 2016;16(1):781.
Mele L, et al. Evaluation and isolation of cancer stem cells using ALDH activity assay. Methods Mol Biol. 2018;1692:43–8.
Khorrami S, et al. Verification of ALDH activity as a biomarker in colon cancer stem cells-derived HT-29 cell line. Iran J Cancer Prev. 2015;8(5):e3446.
Toledo-Guzmn ME, et al. ALDH as a stem cell marker in solid tumors. Curr Stem Cell Res Ther. 2019;14(5):375–88.
Yaghjyan L, et al. Associations of mammographic breast density with breast stem cell marker-defined breast cancer subtypes. Cancer Causes Control. 2019;30(10):1103–11.
Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet. 2000;38(4):291–304.
Dylla SJ, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE. 2008;3(6):e2428.
Vasiliou V, et al. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev. 2004;36(2):279–99.
Mordvinov VA, et al. ABC transporters in the liver fluke Opisthorchis felineus. Mol Biochem Parasitol. 2017;216:60–8.
Mächtel R, et al. An integrated transport mechanism of the maltose ABC importer. Res Microbiol. 2019;170(8):321–37.
Liu X. ABC family transporters. Adv Exp Med Biol. 2019;1141:13–100.
Amawi H, et al. ABC transporter-mediated multidrug-resistant cancer. Adv Exp Med Biol. 2019;1141:549–80.
El-Awady R, et al. The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy. Front Pharmacol. 2016;7:535.
Cui H, et al. ABC transporter inhibitors in reversing multidrug resistance to chemotherapy. Curr Drug Targets. 2015;16(12):1356–71.
Hu Y, et al. Reversal effects of local anesthetics on P-glycoprotein-mediated cancer multidrug resistance. Anticancer Drugs. 2017;28(3):243–9.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92.
Ashley N, et al. Cellular polarity modulates drug resistance in primary colorectal cancers via orientation of the multidrug resistance protein ABCB1. J Pathol. 2019;247(3):293–304.
Zolnerciks JK, et al. The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle. FASEB J. 2014;28(10):4335–46.
Peterson BG, et al. High-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1). Pharmacol Res. 2017;119:313–26.
Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011;278(18):3226–45.
Leslie EM, et al. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216–37.
Pascolo L, et al. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun. 2003;303(1):259–65.
Johnson ZL, Chen J. ATP binding enables substrate release from multidrug resistance protein 1. Cell. 2018;172(1–2):81-9.e10.
Hooijberg JH, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59(11):2532–5.
Leonard GD, et al. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411–24.
Nasr R, et al. Molecular analysis of the massive GSH transport mechanism mediated by the human multidrug resistant protein 1/AB,CC1. Sci Rep. 2020;10(1):7616.
Doyle LA, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665–70.
Fujita K, Ichida K. ABCG2 as a therapeutic target candidate for gout. Expert Opin Ther Targets. 2018;22(2):123–9.
Sarkadi B et al. The ABCG2/BCRP transporter and its variants - from structure to pathology. FEBS Lett. 2020.
Polgar O, et al. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol. 2008;4(1):1–15.
Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update. AAPS J. 2015;17(1):65–82.
Goodell MA, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797–806.
Zhou S, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7(9):1028–34.
Wang XK, et al. Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells. Cancer Res. 2014;74(16):4431–45.
Rahmani F, et al. Role of Wnt/β-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer. J Cell Physiol. 2018;233(2):811–7.
Chikazawa N, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 2010;30(6):2041–8.
Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468–76.
Yamada T, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res. 2000;60(17):4761–6.
Ghandadi M, et al. Wnt-β-catenin signaling pathway, the Achilles’ heels of cancer multidrug resistance. Curr Pharm Des. 2019;25(39):4192–207.
Itaba N, et al. Human mesenchymal stem cell-engineered hepatic cell sheets accelerate liver regeneration in mice. Sci Rep. 2015;5:16169.
Urushibara S, et al. WNT/β-catenin signaling inhibitor IC-2 suppresses sphere formation and sensitizes colorectal cancer cells to 5-fluorouracil. Anticancer Res. 2017;37(8):4085–91.
Hu YB, et al. Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance. Oncogene. 2019;38(11):1951–65.
Cheng X, et al. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer. Biomed Pharmacother. 2019;110:473–81.
Vinson KE, et al. The Notch pathway in colorectal cancer. Int J Cancer. 2016;138(8):1835–42.
Baker A, et al. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018;37(33):4489–504.
Meng RD, et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69(2):573–82.
Huang R, et al. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. Mol Med Rep. 2015;12(2):2417–24.
Li L, et al. KCTD12 regulates colorectal cancer cell stemness through the ERK pathway. Sci Rep. 2016;6:20460.
Fanale D, et al. Non-coding RNAs functioning in colorectal cancer stem cells. Adv Exp Med Biol. 2016;937:93–108.
Hutvgner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297(5589):2056–60.
Yu Y, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis. 2012;33(1):68–76.
Siemens H, et al. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013;4(9):1399–415.
Wang J, et al. The role of MicroRNAs in the chemoresistance of breast cancer. Drug Dev Res. 2015;76(7):368–74.
Ye J, et al. MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. Mol Med Rep. 2017;15(3):1037–42.
Song B, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010;9:96.
Xu XT, et al. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer. 2012;106(7):1320–30.
Shen WW, et al. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med. 2013;91(8):989–1000.
Zhang J, et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011;117(1):86–95.
Yu Y, et al. miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer. 2015;14:98.
Dou J, et al. Decreasing lncRNA HOTAIR expression inhibits human colorectal cancer stem cells. Am J Transl Res. 2016;8(1):98–108.
Ouyang S, et al. LncRNA BCAR4, targeting to miR-665/STAT3 signaling, maintains cancer stem cells stemness and promotes tumorigenicity in colorectal cancer. Cancer Cell Int. 2019;19:72.
Zhao Y, et al. P53–R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs. J Exp Clin Cancer Res. 2019;38(1):379.
Zhou H, et al. LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2020;121(3):2510–24.
Yu Y, et al. A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 2017;16(1):155.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84.
Cao H, et al. Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol Res Pract. 2015;211(8):557–69.
Wong SHM, et al. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11–22.
Hu JL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91.
Weng W, Goel A. Curcumin and colorectal cancer: an update and current perspective on this natural medicine. Semin Cancer Biol. 2020.
Toden S, et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 2015;36(3):355–67.
Machida K. Existence of cancer stem cells in hepatocellular carcinoma: myth or reality? Hepatol Int. 2017;11(2):143–7.
Choi JE, et al. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: clinicopathological significance. Oncol Rep. 2017;38(3):1695–705.
Hwang WL, et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology. 2011; 141(1):279–91, 91.e1–5.
Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol. 2013;14(6):329–40.
Vira D, et al. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012;31(3–4):733–51.
Vasan N, et al. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
Gonzalez H, et al. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84.
Luo M, et al. Stem cell quiescence and its clinical relevance. World J Stem Cells. 2020;12(11):1307–26.
Francescangeli F, et al. A pre-existing population of ZEB2(+) quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):2.
Dieter SM, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell. 2011;9(4):357–65.
Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23–44.
Weitz J, et al. Colorectal cancer. Lancet. 2005;365(9454):153–65.
Ba-Sang DZ, et al. A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer. Oncotarget. 2016;7(51):84468–79.
Xie YH, et al. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.
Zhou Y, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9(70):33403–15.
Sand A, et al. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer. Cancer Lett. 2020;472:119–31.
Barker N, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449(7165):1003–7.
Lv L, et al. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumour Biol. 2016;37(7):8811–24.
Gottesman MM, et al. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
Corrêa S, et al. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 2012;12:303.
Yu Y, et al. Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol. 2013;6(2):180–6.
This work was supported by National Natural Science Foundation of China (81472275), Natural Science Foundation of Guangdong Province (2020A151501303, 2014A030313542), Major projects of key platforms for colleges and universities in Guangdong Province (2020KTSCX045, 2019KTSCX046), and Research Fund of Guangdong Medical University (GDMUZ2020001).
Conflict of interest
All authors announce that they have no conflicts of interest.
Consent for publication
All listed authors were actively involved in the study, reviewed, and approved the submitted manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lei, X., He, Q., Li, Z. et al. Cancer stem cells in colorectal cancer and the association with chemotherapy resistance. Med Oncol 38, 43 (2021). https://doi.org/10.1007/s12032-021-01488-9
- Colorectal cancer
- Cancer stem cells
- Surface markers
- Chemotherapeutic resistance